LP
PBYI icon

LMR Partners’s Puma Biotechnology PBYI Stock Holding History

LMR Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,006
Closed -$58.3K – 1258
2024
Q1 		$58.3K Buy
+11,006
New +$59.3K ﹤0.01% 975
2022
Q4 		– Sell
-11,514
Closed -$27K – 1228
2022
Q3 		$27K Hold
11,514
– – ﹤0.01% 1143
2022
Q2 		$33K Buy
+11,514
New +$28.6K ﹤0.01% 1193
2016
Q1 		– Sell
-9,402
Closed -$737K – 413
2015
Q4 		$737K Buy
+9,402
New +$738K 0.24% 88
2015
Q2 		– Sell
-7,122
Closed -$1.68M – 588
2015
Q1 		$1.68M Sell
7,122
-69,697
-91% -$14.9M 0.23% 121
2014
Q4 		$14.5M Buy
76,819
+20,187
+36% +$4.48M 1.9% 9
2014
Q3 		$13.5M Buy
+56,632
New +$11.6M 1.08% 36

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's PBYI Position: Q2 2024 in Review

LMR Partners sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 11,006 shares — an estimated $58.3K sold.

LMR Partners first reported a position in PBYI in Q3 2014 and held it in 7 quarters. The position peaked at $14.5M in Q4 2014. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • LMR Partners reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 11,006 Puma Biotechnology shares in Q2 2024, an estimated $58.3K.
  • LMR Partners first reported a position in Puma Biotechnology in Q3 2014 and held it in 7 quarters.
  • LMR Partners's Puma Biotechnology position peaked at $14.5M in Q4 2014.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.